Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Single-Cell Omics Market by Type (Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics), by Application (Oncology, Cell Biology, Neurology, Immunology, Others) and by End User (Academic Research Institutes, Biopharmaceutical Companies, Contract Research Organization, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13231

Pages: NA

Charts: NA

Tables: NA

Single Cell Omics Market Overview 2030

Single cell omics is a technology which refers to multiple types of molecules such as DNA, RNA, protein, and chromatin from individual cells. This can be used in study of biological insight and analysis of each molecular layer from separate cells. Moreover, this can be used in analysis of genome, epigenome, trascriptome, proteome, and metabolome lineages. Single cell omics technology divided into genotypic and phenotypic which help to determine the mechanisms of the diseases. Single cell omics technology can help to construct multiple profiles of same cell. Single cell omics also enhance the understanding of cellular properties and architecture of heterogeneous tissue. This technology has great potential in virus biology and virus host interactions.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

There has been an increase in the demand for medical supplies to take care of infected population. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. There is an increase in the need for medical supplies, both from healthcare professionals and civil population for precautionary measures, owing to the rise in number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Therefore, COVID-19 is expected to have a significant impact on the single cell omics market.

Top Impacting Factors

  • Rise in cases of chronic diseases, increase in incidence of genetic disorders, surge in outbreak of viruses such as COVID-19 & H1N1, rise in number of pharmaceutical & biotechnological industries, surge in usage of large scale genomics studies, and increase in disposable incomes across the globe are the key factors that drive the growth of single cell omics market.
  • In addition, surge in adoption of advance research technologies, increase in usage of personalized medication, surge in R & D activities for development of novel drugs, continuous mutations of microorganisms leading to new strain of viruses, and increase in investment on healthcare sector are some factors that fuel the growth of single cell omics market.
  • However, high cost associated with single cell analysis hinder the growth of market.
  • Contrarily, rise in single cell technology solutions for the development of therapeutic drugs and government initiatives for regulatory approvals are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Mission Bio announced launch of single cell multi omics system. This system is faster and more successful in development of precision cancer therapies and helpful in reduction of high cost of cancer treatment drugs.

In 2018, Proteona announced launch of ESCAPE RNA sequencing for ProteoGeneomics. This device helps in enhanced single cell analysis with protein expression.

Key Benefits of the Report

  • This study presents the analytical depiction of single cell omics market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the single cell omics market share.
  • The current market is quantitatively analyzed to highlight the single cell omics market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Single Cell Omics Market Report                        

  • Which are the leading players active in the single cell omics market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "single cell omics"?
  • What is "single cell omics" market prediction in the future?
  • Who are the leading global players in the "single cell omics" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "single cell omics" market report?

 Key Market Segments

  • By Type
    • Single Cell Genomics
    • Single Cell Proteomics
    • Single Cell Transcriptomics
    • Single Cell Metabolomics
  • By Application
    • Oncology
    • Cell Biology
    • Neurology
    • Immunology
    • Others
  • By End User
    • Academic & Research Institutes
    • Biopharmaceutical Companies
    • Contract Research Organization
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • NanoString Technologies
  • MissionBio
  • 10x Genomics
  • Fluxion Biosciences
  • Fluidigm Corporation
  • Bio-Rad Laboratories
  • GE LifeSciences
  • 1CellBio
  • Celsee
  • Takara Bio.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: SINGLE-CELL OMICS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Single Cell Genomics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Single Cell Proteomics

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Single Cell Transcriptomics

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Single Cell Metabolomics

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: SINGLE-CELL OMICS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Oncology

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Cell Biology

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Neurology

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Immunology

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: SINGLE-CELL OMICS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Academic And Research Institutes

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Biopharmaceutical Companies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Contract Research Organization

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: SINGLE-CELL OMICS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Single-cell Omics Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Single-cell Omics Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Single-cell Omics Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Single-cell Omics Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Single-cell Omics Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Single-cell Omics Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Single-cell Omics Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Single-cell Omics Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Single-cell Omics Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Single-cell Omics Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Single-cell Omics Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Single-cell Omics Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Single-cell Omics Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Single-cell Omics Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Single-cell Omics Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Single-cell Omics Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Single-cell Omics Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Single-cell Omics Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Single-cell Omics Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Single-cell Omics Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Single-cell Omics Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Single-cell Omics Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Single-cell Omics Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Single-cell Omics Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Single-cell Omics Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bio-Rad Laboratories

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Celsee

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. NanoString Technologies

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. 1CellBio

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. 10x Genomics

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. MissionBio

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. GE LifeSciences

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Fluxion Biosciences

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Fluidigm Corporation

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Takara Bio.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL SINGLE-CELL OMICS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL SINGLE-CELL OMICS MARKET FOR SINGLE CELL GENOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL SINGLE-CELL OMICS MARKET FOR SINGLE CELL PROTEOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL SINGLE-CELL OMICS MARKET FOR SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL SINGLE-CELL OMICS MARKET FOR SINGLE CELL METABOLOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL SINGLE-CELL OMICS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL SINGLE-CELL OMICS MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL SINGLE-CELL OMICS MARKET FOR CELL BIOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL SINGLE-CELL OMICS MARKET FOR NEUROLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL SINGLE-CELL OMICS MARKET FOR IMMUNOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL SINGLE-CELL OMICS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL SINGLE-CELL OMICS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL SINGLE-CELL OMICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL SINGLE-CELL OMICS MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL SINGLE-CELL OMICS MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL SINGLE-CELL OMICS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL SINGLE-CELL OMICS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA SINGLE-CELL OMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. U.S. SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. U.S. SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. U.S. SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. CANADA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. CANADA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. CANADA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. MEXICO SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. MEXICO SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE SINGLE-CELL OMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. EUROPE SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. FRANCE SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. FRANCE SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 39. GERMANY SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 40. GERMANY SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. ITALY SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. ITALY SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. ITALY SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SPAIN SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 46. SPAIN SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. UK SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. UK SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. UK SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. RUSSIA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 52. RUSSIA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. REST OF EUROPE SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. REST OF EUROPE SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC SINGLE-CELL OMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. ASIA-PACIFIC SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. CHINA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. CHINA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. CHINA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. JAPAN SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 65. JAPAN SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. INDIA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. INDIA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. INDIA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH KOREA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 71. SOUTH KOREA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 73. AUSTRALIA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 74. AUSTRALIA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. THAILAND SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 77. THAILAND SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 79. MALAYSIA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 80. MALAYSIA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 82. INDONESIA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 83. INDONESIA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA SINGLE-CELL OMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 90. LAMEA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 92. BRAZIL SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 93. BRAZIL SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 96. SOUTH AFRICA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 98. SAUDI ARABIA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 99. SAUDI ARABIA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 100. UAE SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 101. UAE SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 102. UAE SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 104. ARGENTINA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 105. ARGENTINA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA SINGLE-CELL OMICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 107. REST OF LAMEA SINGLE-CELL OMICS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 108. REST OF LAMEA SINGLE-CELL OMICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 109. BIO-RAD LABORATORIES: KEY EXECUTIVES
  • TABLE 110. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 111. BIO-RAD LABORATORIES: OPERATING SEGMENTS
  • TABLE 112. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 113. BIO-RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. CELSEE: KEY EXECUTIVES
  • TABLE 115. CELSEE: COMPANY SNAPSHOT
  • TABLE 116. CELSEE: OPERATING SEGMENTS
  • TABLE 117. CELSEE: PRODUCT PORTFOLIO
  • TABLE 118. CELSEE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. NANOSTRING TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 120. NANOSTRING TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 121. NANOSTRING TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 122. NANOSTRING TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 123. NANOSTRING TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. 1CELLBIO: KEY EXECUTIVES
  • TABLE 125. 1CELLBIO: COMPANY SNAPSHOT
  • TABLE 126. 1CELLBIO: OPERATING SEGMENTS
  • TABLE 127. 1CELLBIO: PRODUCT PORTFOLIO
  • TABLE 128. 1CELLBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. 10X GENOMICS: KEY EXECUTIVES
  • TABLE 130. 10X GENOMICS: COMPANY SNAPSHOT
  • TABLE 131. 10X GENOMICS: OPERATING SEGMENTS
  • TABLE 132. 10X GENOMICS: PRODUCT PORTFOLIO
  • TABLE 133. 10X GENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. MISSIONBIO: KEY EXECUTIVES
  • TABLE 135. MISSIONBIO: COMPANY SNAPSHOT
  • TABLE 136. MISSIONBIO: OPERATING SEGMENTS
  • TABLE 137. MISSIONBIO: PRODUCT PORTFOLIO
  • TABLE 138. MISSIONBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. GE LIFESCIENCES: KEY EXECUTIVES
  • TABLE 140. GE LIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 141. GE LIFESCIENCES: OPERATING SEGMENTS
  • TABLE 142. GE LIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 143. GE LIFESCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. FLUXION BIOSCIENCES: KEY EXECUTIVES
  • TABLE 145. FLUXION BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 146. FLUXION BIOSCIENCES: OPERATING SEGMENTS
  • TABLE 147. FLUXION BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 148. FLUXION BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. FLUIDIGM CORPORATION: KEY EXECUTIVES
  • TABLE 150. FLUIDIGM CORPORATION: COMPANY SNAPSHOT
  • TABLE 151. FLUIDIGM CORPORATION: OPERATING SEGMENTS
  • TABLE 152. FLUIDIGM CORPORATION: PRODUCT PORTFOLIO
  • TABLE 153. FLUIDIGM CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. TAKARA BIO.: KEY EXECUTIVES
  • TABLE 155. TAKARA BIO.: COMPANY SNAPSHOT
  • TABLE 156. TAKARA BIO.: OPERATING SEGMENTS
  • TABLE 157. TAKARA BIO.: PRODUCT PORTFOLIO
  • TABLE 158. TAKARA BIO.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL SINGLE-CELL OMICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL SINGLE-CELL OMICS MARKET
  • FIGURE 3. SEGMENTATION SINGLE-CELL OMICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN SINGLE-CELL OMICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSINGLE-CELL OMICS MARKET
  • FIGURE 11. SINGLE-CELL OMICS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. SINGLE-CELL OMICS MARKET FOR SINGLE CELL GENOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. SINGLE-CELL OMICS MARKET FOR SINGLE CELL PROTEOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. SINGLE-CELL OMICS MARKET FOR SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. SINGLE-CELL OMICS MARKET FOR SINGLE CELL METABOLOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. SINGLE-CELL OMICS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 17. SINGLE-CELL OMICS MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. SINGLE-CELL OMICS MARKET FOR CELL BIOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. SINGLE-CELL OMICS MARKET FOR NEUROLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. SINGLE-CELL OMICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. SINGLE-CELL OMICS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. SINGLE-CELL OMICS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 23. SINGLE-CELL OMICS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. SINGLE-CELL OMICS MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. SINGLE-CELL OMICS MARKET FOR CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. SINGLE-CELL OMICS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 31. COMPETITIVE DASHBOARD
  • FIGURE 32. COMPETITIVE HEATMAP: SINGLE-CELL OMICS MARKET
  • FIGURE 33. TOP PLAYER POSITIONING, 2024
  • FIGURE 34. BIO-RAD LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. BIO-RAD LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. BIO-RAD LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. CELSEE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. CELSEE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. CELSEE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. NANOSTRING TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. NANOSTRING TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. NANOSTRING TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. 1CELLBIO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. 1CELLBIO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. 1CELLBIO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. 10X GENOMICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. 10X GENOMICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. 10X GENOMICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. MISSIONBIO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. MISSIONBIO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. MISSIONBIO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. GE LIFESCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. GE LIFESCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. GE LIFESCIENCES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. FLUXION BIOSCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. FLUXION BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. FLUXION BIOSCIENCES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. FLUIDIGM CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. FLUIDIGM CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. FLUIDIGM CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. TAKARA BIO.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. TAKARA BIO.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. TAKARA BIO.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Single-Cell Omics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved